Anti-PD-1 and PD-L1 antibodies, such as Nivolumab and Pembrolizumab, have displayed a manageable safety and promising efficacy to reduce tumor burden for patients with advanced gastric cancer (2, 3). The gene discussed is CD274; the disease is gastric cancer.